Novartis has asked the court to speed up its ruling in a long-running patent dispute over its heart failure medication, Entresto. The Swiss pharmaceutical giant is engaged in a legal battle with MSN Laboratories over intellectual property rights linked to the drug.
Novartis wants a quick decision to protect its market share as it faces pressure from generic drug makers.
The dispute focuses on MSN’s plan to launch a generic version of Entresto. Novartis claims this move violates its patents. This case has gained attention because it affects both companies and has wider consequences for the pharmaceutical industry. Patent battles like this can shape drug prices, availability, and innovation. Novartis’ call for a faster ruling shows the importance of securing exclusive rights to one of its major products.
Related topics:
Treat Heart Disease as A Lifelong Condition, Western Sydney Health Expert Urges
Johns Hopkins Expands Specialized Heart Failure Care to Greater Washington Region
Standardized TAVR Protocol Improves Outcomes for Heart Patients, Study Finds